uniQure NV (QURE) Trading Down 4.6%
uniQure NV (NASDAQ:QURE) fell 4.6% during mid-day trading on Tuesday . The stock traded as low as $8.46 and last traded at $8.47, with a volume of 124,563 shares trading hands. The stock had previously closed at $8.88.
Several research firms recently issued reports on QURE. Jefferies Group reissued a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Cowen and Company reissued a “buy” rating on shares of uniQure NV in a research note on Thursday, June 2nd. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of uniQure NV in a research note on Wednesday, May 11th. Finally, Piper Jaffray Cos. reissued a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. uniQure NV presently has an average rating of “Buy” and an average price target of $28.10.
The stock’s market capitalization is $204.76 million. The stock has a 50 day moving average of $7.90 and a 200 day moving average of $11.27.
uniQure NV (NASDAQ:QURE) last announced its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. On average, equities research analysts forecast that uniQure NV will post ($3.50) EPS for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.